Procyte Corp. said Monday that it completed two pivotal Phase IIItrials of its wound-healing compound, Iamin gel, for the treatment ofdiabetic plantar ulcers.The Kirkland, Wash., company said results from the trials, whichinvolved 511 people, should be ready for initial data analysis by theend of the year. It was a placebo-controlled, dose-ranging, evaluator-blinded trial.The Phase III trials of the tripeptide copper complex were put on hold_ for four business days _ last December, due to certaincardiovascular events. But the FDA determined the events were relatedto complications of diabetes, and not Iamin.Primary endpoints in the trial include reduction of wound size and thenumber of patients whose ulcers closed. Additional endpoints are rateof wound closure over time and the reduced incidence of ulcerinfection.Karen Hedine, Procyte's vice president, business development, toldBioWorld the company expects to have a pilot Phase II study of Iaminfor pressure sores started by the end of the year. And Procyte recentlycompleted a Phase I study of Iamin-IB for inflammatory bowel disease.Procyte (NASDAQ:PRCY) stock was down 38 cents Monday, closingat $9.13. _ Jim Shrine
(c) 1997 American Health Consultants. All rights reserved.